isomab Overview

  • Year Founded
  • 2022

Year Founded

  • Status
  • Private

  • Employees
  • 9

Employees

  • Latest Deal Type
  • Early Stage VC

  • Latest Deal Amount
  • $9.5M

  • Investors
  • 6

isomab General Information

Description

Developer of isoform-specific antibodies designed to restore blood flow in peripheral arterial disease. The company's platform isoform-specific antibodies altered in disease, the effects of pathogenic messenger ribonucleic acid splicing, and vascular endothelial growth factor A, pro-angiogenic and anti-angiogenic isoforms, increased in many ischaemic diseases, preventing the collateral formation, enabling doctors to treat diseases where patients currently have limited treatment options.

Contact Information

Website
www.isomab.bio
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Biocity Nottingham Innovation Building
  • Pennyfoot Street
  • Nottingham NG1 1GF
  • England, United Kingdom
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Vertical(s)
HealthTech, Life Sciences
Corporate Office
  • Biocity Nottingham Innovation Building
  • Pennyfoot Street
  • Nottingham NG1 1GF
  • England, United Kingdom

isomab Timeline

2023202420252026
Date FoundedFinancing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

isomab Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Early Stage VC 12-Apr-2024 $9.5M Completed Generating Revenue
3. Early Stage VC 12-Dec-2022 Completed Generating Revenue
2. Accelerator/Incubator Completed Generating Revenue
1. University Spin-Out 01-Mar-2022 Completed Generating Revenue
To view isomab’s complete valuation and funding history, request access »

isomab Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series Seed Preferred
Series Seed Preferred
A Ordinary 777,006 $0.000034 $0.77 $0.77 1x $0.77 5.87%
A Ordinary 691,862 $0.000034 $0.61 $0.61 1x $0.61 5.22%
To view isomab’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

isomab Patents

  • 1

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • Pending

  • Expiring in next 12 mo

isomab Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-202404450-D0 Vegf variant antibodies Inactive 27-Mar-2024

isomab Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

isomab Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds
Broadview Ventures Venture Capital Minority
Mercia Ventures Venture Capital Minority
SCVC Venture Capital Minority
University of Bristol University
University of Nottingham University
You’re viewing 5 of 6 investors. Get the full list »

Ready to get started?

Request a free trial

isomab FAQs

  • When was isomab founded?

    isomab was founded in 2022.

  • Where is isomab headquartered?

    isomab is headquartered in Nottingham, United Kingdom.

  • What is the size of isomab?

    isomab has 9 total employees.

  • What industry is isomab in?

    isomab’s primary industry is Biotechnology.

  • Is isomab a private or public company?

    isomab is a Private company.

  • What is the current valuation of isomab?

    The current valuation of isomab is .

  • What is isomab’s current revenue?

    The current revenue for isomab is .

  • How much funding has isomab raised over time?

    isomab has raised $10.5M.

  • Who are isomab’s investors?

    Broadview Ventures, Mercia Ventures, SCVC, University of Bristol, and University of Nottingham are 5 of 6 investors who have invested in isomab.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process